brick: the past few months stuck at .08 cents speaks for itself, in spite of several big catalysts! The confusion about LymPro's revenue that Jason caused is very frustrating to me, and the fact Gerald let it stand. Jason has a close relationship with Gerald and he is the only analyst covering AMBS. His forecast about LymPro was a low blow. I wasn't amused by how the two of them handled Lympro and the way it stifled the stock price.

Hopefully Gerald will make up for it soon.